论文信息 - Letter to the Editor: Drug-Induced Liver Injury with Ritonavir-Boosted Nirmatrelvir: Evidence from COVID-19 EUA Adverse Event Reporting System - Authors’ reply - 字舞流文

Letter to the Editor: Drug-Induced Liver Injury with Ritonavir-Boosted Nirmatrelvir: Evidence from COVID-19 EUA Adverse Event Reporting System - Authors’ reply

Grace Lai-Hung Wong | Terry Cheuk-Fung Yip | Vicki Wing-Ki Hui

[1] V. Wong,et al. Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir , 2022, JAMA network open.

[2] V. Wong,et al. Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir , 2022, Gastroenterology.

[3] V. Wong,et al. Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4] M. Bhat. Multi-omic Characterization of COVID Hepatitis , 2022, Gastroenterology.

[5] G. Wong,et al. Management of hepatitis B virus reactivation due to treatment of COVID-19 , 2022, Hepatology International.

[6] V. Wong,et al. Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID‐19 , 2021, Hepatology.

[7] V. Wong,et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement , 2020, The Lancet Gastroenterology & Hepatology.